David W. Osborne - Mar 1, 2022 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Signature
/s/ Scott Burrows, as Attorney-in-Fact for David W. Osborne, Ph.D.
Stock symbol
ARQT
Transactions as of
Mar 1, 2022
Transactions value $
-$13,758
Form type
4
Date filed
3/3/2022, 03:18 PM
Next filing
Mar 7, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARQT Common Stock Sale -$13.8K -775 -0.31% $17.75 247K Mar 1, 2022 Direct F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs"). Shares and RSUs remain subject to a lock-up agreement with the underwriters for the Issuer's follow-on offering in February 2021.
F2 The transaction was executed in multiple trades in prices ranging from $17.40 to $18.185, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 Includes 1,004 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as follows: 976 shares on May 31, 2021 and 28 shares on November 30, 2021.
F4 Includes 14,000 RSUs.